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Abstract
Depression is a mental disorder with a high
prevalence among patients with end stage
renal disease (ESRD). It is reported that
depression afflicts approximately 20-30% of
this patient population, being associated,
amongst other, with high mortality rate, low
adherence to medication and low perceived
quality of life. There is a variety of medications
known to be effective for the treatment of
depression but due to poor adherence to treat-
ment as well as due to the high need for med-
ications addressing other ESRD comorbidities,
depression often remains untreated. According
to the literature, depression is under-diag-
nosed and undertreated in the majority of the
patients with chronic kidney disease. In the
current review the main pharmacological and
non-pharmacological approaches and research
outcomes for the management of depressive
symptoms in hemodialysis patients are dis-
cussed.
Introduction
End stage renal disease (ESRD) treated with
hemodialysis (HD), is often associated with
several comorbidities like hypertension, heart
diseases, musculoskeletal problems and dia-
betes mellitus.1 Patients receiving HD therapy
exhibit low levels of perceived quality of life,
usually accompanied by significant emotional
distress characteristics such as symptoms of
depression and anxiety.2 According to the litera-
ture, depression is the most common mental
disorder in HD patients affecting approximately
the 20% of this specific patients group and
reported to be the second only to hypertension
in frequency as a comorbid diagnosis.3-5 The
last decade, nephrologists have looked system-
atically for signs of depression since depression
is recognized as an important factor which
among others, influences the overall health sta-
tus and survival of the patient.6
The aim of this review is to describe and
cover in critical fashion the various treatment
options available for the management of
depression in patients receiving HD therapy
and whether those regimes are effective in
improving patients’ mental health. Depression in hemodialysis patientsDefinition
According to the 4th edition of the
Diagnostic and Statistical Manual of Mental
Disorders (DMS-IV), depression is defined by
having a loss of pleasure or interest for at least
a two week period, accompanied by 5 or more
psychological, somatic and behavioral symp-
toms. It is noteworthy that the World Health
Organization ranks depression as the leading
cause of disability and the fourth leading con-
tributor to the global burden of disease in 2000
worldwide.7 The same organization’s projec-
tions indicate that depression will be the high-
est ranked cause of disease burden in devel-
oped countries by the year 2020. Sadness, emo-
tional inhibitions, fatigue, sleep disturbances,
loss of concentration, intense guilt, and
thoughts of suicide or death are some of the
symptoms associated with major depression
while thoughts of suicide and death are partic-
ular symptoms that are of great concern for the
general public.8,9Epidemiology
According to the World Health Organization
(WHO) depression is considered to be the sec-
ond most common condition in the general
population with the reported prevalence of life-
time depression to be around 16%.10 Research
findings suggest that the prevalence of depres-
sion in the general population is about 12-
20%,11 with women reporting higher scores
compared to men. In a large WHO study with
245,404 participants from 60 countries from all
regions of the world, the prevalence of depres-
sion based on ICD-10 criteria was 3.2%, while
interestingly, in patients with one or more
chronic disease the prevalence of depression
climbed between 9.3% and 23.0%.12 In a very
recent cross-national study from 18 countries
the average lifetime and 12-month prevalence
of depression were 14.6% and 5.5% respective-
ly in the high-income counties and 11.1% and
5.9% respectively in the low- to middle-income
countries.13 Depression is one of the most
common psychiatric abnormalities in patients
with ESRD,14,15 affecting approximately 20-
30% of the patients,16-18 with some studies
reporting even higher percentages.19 
Etiology of depression in hemodialy-sis patients 
Causes of depression are linked also to the
dialysis treatment per se, which requires from
a patient to stay attached to the dialysis
machine for approximately 4 hours, 3 times a
week, a necessity that contributes signifi-
cantly to a patient’s low quality of life and
restricts independent living.20 It is noteworthy
that health care providers frequently fail to
identify and/or treat depression in HD
patients (70%) despite the high prevalence of
the disease.21 In addition, factors such as
medication side effects and dietary restric-
tions may further contribute to the impaired
levels of perceived quality of life and the emo-
tional distress experience by the HD popula-
tion, leading to more severe symptoms.22,23
Other factors that could be blamed for the
high prevalence of depression in HD patients
are social in nature such as work loss, alter-
ations in one’s family role, experience of mul-
tiple losses, medication adherence,14,23-25 low
monthly income, years on dialysis and unem-
ployment.26,27 Further, there is some evidence
suggesting that depression in HD patients
could be the result of factors such as a decline
in cognitive skills and sexual function,28,29 as
well as low education levels.30 It’s important to
recognize that HD patients face many addi-
tional challenges which increase the possibil-
ity of developing depression or anxiety or
other mental conditions. Patients experience
major changes in their lifestyle. On the one
hand they have very limited, if any, alterna-
tive options to the proposed or available treat-
ment of their end-stage renal disease state
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(which requires strict compliance to their
dialysis and medicinal regime). This includes
having to adjust to a rigorous dietary pre-
scription and a very limited fluid intake.  On
the other hand, it also becomes a challenge
for many HD patients to maintain meaningful
life roles regarding employment, family life,
and friendships. HD patients have not only to
cope with the anger, fear, anxiety, frustration,
and sadness of having a serious chronic ill-
ness but have also to accept a curtailment of
their independence. Finally they have to con-
front their own mortality and the likelihood of
a shortened life span.31 Depression in HD
patients is characterized by both cognitive
and somatic features. The problem is that
somatic features of depression such as
anorexia, sleep disturbances, fatigue and gas-
trointestinal disorders, are also common
symptoms of uremia.32,33 For this reason
there is added difficulty in diagnosing depres-
sion in HD patients, i.e. the identifying a
mental illness against the backdrop of the
physical illness.14,34-36 It is also challenging to
distinguish the non-uremia induced depres-
sive symptoms from known uremic-induced
symptoms such as irritability, cognitive dys-
function, or mild symptoms of encephalopa-
thy or from drug effects or symptoms of inad-
equate dialysis. It is noteworthy that depres-
sion as a mental disorder when it coexists
with another psychiatric or medical illness,
may render depression relatively to treat-
ment.14,35-38Research questions and searchstrategy
The primary questions of this review were:
what are the main pharmacological and non-
pharmacological approaches and research
outcomes for the reduction of symptoms of
depression in HD patients? The following
databases were searched: MEDLINE,
PUBMED, PsycINFO and SCOPUS. The key-
words used were: hemodialysis, end stage
renal diseases, renal failure, depression,
depressive symptoms, pharmacological, non
pharmacological, alternative medicine, exer-
cise, medication, drugs, quality of life. We
organized our evaluation of the literature in
the following sections: measurement of
depression, treatment options including phar-
macological management, 1st generation
antidepressants, 2nd generation antidepres-
sants, non-pharmacological management,
including psychotherapeutic approach, alter-
native therapeutic approaches and exercise.
We strived to gather information pertaining
to ESRD-HD patients but when not available
we report on studies within the chronic renal
disease spectrum.
Measurement of depression
The Beck Depression Inventory (BDI) is one
of the most established instruments used to
measure the presence and severity of depres-
sion. It is a 21-question inventory developed to
measure the degree and severity of the depres-
sion’s symptoms.39 A score of 14-16 or more
has been reported to be an accurate measure
for the diagnosis of depression in the HD pop-
ulation and has been successfully used, in its
original or revised forms.40 Also, one of the
most frequently used personality tests is the
Minnesota Multiphasic Personality Inventory
(MMPI).40 It’s a self-report instrument and
contains 566 positive statements dealing with
thoughts, feelings, attitudes, physical symp-
toms and quality of life.41,42
Many times instruments assessing aspects
of quality of life (QoL) are also used for assess-
ing mental health. The most common ques-
tionnaire found in the literature is the SF-36
questionnaire − a self-administered instru-
ment containing 36 items,43 which assesses
health related QoL on eight multi-item dimen-
sions, including vitality and mental health.
In clinical practice, the Nine-Question
Patient Health Questionnaire (PHQ-9),44 a self-
report instrument, is often used to detect five
common mental disorders in primary care:
depression, anxiety, alcohol abuse, somato-
form disorder, and eating disorder. Another
instrument used for measuring depression is
the Hamilton Rating Scale for Depression.45
The questionnaire lists 21-items and rates the
severity of symptoms observed in depression
such as low mood, insomnia, agitation, anxiety
and weight loss.46 Moreover, an appropriate
tool for assessing depressive symptomatology
in the general population is the Center for
Epidemiologic Studies Depression Scale
(CED).47 A self-report questionnaire, that con-
tains 20 items and asks caregivers to rate how
often over the past week they experienced
symptoms associated with depression, such as
restless sleep, poor appetite, and feeling lonely.
Additionally, the Zung Self-Rating Depression
Scale contains 20 items,48 ten positively word-
ed and ten negatively worded questions,
assessing the level of depression or depressive
symptoms.49,50
Treatment options
According to the literature, depression is not
only under-diagnosed, but it is also undertreat-
ed in patients with chronic kidney disease.51 In
the following text, the main pharmacological
and non-pharmacological approaches and
research outcomes for the reduction of depres-
sion symptoms in HD patients are discussed.Pharmacological management 
Multiple classes of medications are available
for treatment of depression in the patient with
chronic diseases. Despite the availability of
high-tech brain imaging systems, health care
providers have to prescribe antidepressants
using their clinical judgment and other factors
such as effectiveness, toxicity, expense, and
ease of administration. Most studies support
that low doses of antidepressant medications
can have therapeutic results in patients main-
tained on dialysis (Table 1).52-67 There are 2
classes of medication with proven benefits for
the depressed patient divided in 1st and 2nd gen-
eration.First generation antidepressants
Desipramine and tricyclic antidepressants
(TCAs) are used orally for treating major
depressive disorder. TCAs have been used clin-
ically to treat patients with major depressive
illness since the early 1960s. In a small study,
the use of TCAs showed a positive effect in HD
patients’ levels of depression  while in a study
by Lee and colleagues (2004),54 antidepressant
treatment decreased the serum level of inter-
leukin-beta1 and increased the serum level of
interleukin-6 improving patients’ depression
symptoms’ severity with parallel improvements
in various immunological and nutritional
indices.54 Other pharmacological options for
the treatment of depression include
monoamine oxidase inhibitors (MAOI) and
reverse inhibitors of MAO.28,68,69Second generation antidepressants
The second generation of antidepressants
consists of a category called selective seroto-
nine reuptake inhibitors (SSRIs) including
venlafaxine, mirtazapine, bupropion, nefa-
zodone, duloxetine, fluoxetine and fluvoxam-
ine. These act on the central nervous system
through their effects on neurotransmitters
such as serotonin, norepinephrine, or
dopamine. Koo and colleagues (2005) exam-
ined the effect of antidepressant treatment in
HD patients treated with paroxetine for 8
weeks and found a significant improvement in
depressive symptoms.55 In one study the safety
of fluoxetine in patients with kidney disease
was assessed. Specifically nine depressive
patients with normal renal failure and seven
HD patients were given fluoxetine 20 mg/d in
an 8 week study. Depression was assessed by
HAMD-17, BDI, Montgomery Asberg
Depression Rating Scale, Brief Symptom
Inventory, Global Well-being Scale, and the
Electronic Visual Analog Scale before, during
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and at the conclusion of the 8-week study peri-
od. Five of six patients in both the ESRD group
and the normal renal function group experi-
enced significant decreases in their overall
depression scores with an approximately 25%
reduction in the HAMD-17 score.57
In an another study, the authors found that
8 weeks of SSRIs treatment was enough to
improve depression with a concomitant
improvement in quality of patients’ life.56 A
year later Kalender et al., (2007) treated HD,
peritoneal dialysis and pre-dialysis patients
with citalopram, and found very similar
results.70Non-pharmacological management 
There is a wide spectrum of non-pharmaco-
logical and psychotherapeutic techniques for
the management of depression in HD
patients.71 In the text below the main non-
pharmacological treatment options are dis-
cussed exploring in depth their effectiveness
and potential for use in this group of patients. 
Psychotherapeutic approach
Cognitive Behavioral Therapy (CBT) can be
characterized as a comprehensive system of
psychotherapy which combines both behavior
theory and cognitive learning theory and
implements strategies to change chronic
patients’ way of thinking and attitudes.72,73
Current evidence shows that depression is an
important target of psychological assessment
in HD patients, further supported by evidence
showing a significant improvement in the
mood of these patients.58 Consistent with pre-
vious studies, HD patients who had the oppor-
tunity to engage in cognitive behavioral thera-
py and to share their feelings concerning their
disease, exhibit lower levels of depression and
stress.74 Similar improvements were present-
ed in the study by Lii et al., where group ther-
apy successfully reduced patient’s depression
symptoms.59 Furthermore, support from the
family and the immediate social circle can
decrease depression symptoms by improving
patients’ self-esteem.75 
Recently, a structured psychological inter-
vention was successfully applied in ESRD
patients resulting in significant improvements
in emotional distress indices such as depres-
sion, anxiety and worries thoughts leading to a
parallel improvement of patient’s QoL score.60 
Relaxation and imagery techniques have
been successfully applied in patients with
chronic disease in order to reduce depression
symptoms.61 However, it seems that those
techniques may not be as effective in HD
patients, despite the fact that the patient’s
adherence to interventions and their self-sat-
isfaction was significantly improved.76 Tsay
and Hung (2004) examined the effects of an
empowerment intervention program in HD
patients indicating a significant improvement
both in depression symptoms as well as in self-
care and self-efficacy of the participants.62
Even though these techniques look very prom-
ising for the amelioration or therapy of depres-
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Table 1. Overview of depression treatment in hemodialysis patients.
Reference                  Intervention                    Diagnosis                 Period              Methodology                              Outcomes
Wuerth et al.52            7 (patients) sertraline,           Clinical depression             12 weeks                   BDI, HAMD,                                        Improvement
                                                2 bupropion,                                                                                                  psychiatric interview                     in depressive symptoms
                                                2 nefazodone                                       
Kennedy et al.53                 Antidepressant                    Major depression                7 weeks             BDI, HAMD, MMSE,                           Significant recovery
                                        therapy (not stated)                                                                                   standardized antidepressant, in five patients, improvement in one, 
                                                                                                                                                                          side effect checklist                and discontinuation of therapy 
                                                                                                                                                                                                                                         in the remaining two
Lee et al.54                       20 mg of fluoxetine                 Depressed mood                8 weeks                         HAMD                   >50% reduction in the score of the HAND
Koo et al.55                    Paroxetine 10 mg/day                   Not specified                    8 weeks                            BDI                  Changes in depression and nutritional status
Turk et al.56                 Sertralin HCl, 50 mg/day         Patients who had BDI            8 weeks                            BDI                                        Improvement in QOL
                                                                                      score ≥15 were diagnosed 
                                                                                                   as depressed
Levy et al.57                   Fluoxetine 20 mg/day                     Depression                     8 weeks            DSM-III-R, HAMD-17         Improvement in depressive symptoms
Koo et al.55                     Paroxetine 10 mg/day           Depressive symptoms            8 weeks                     BDI, HAMD                 Improvement in depressive symptoms 
                                                                                                                                                                                                                                         and nutritional status
Turk et al.56                Sertralin HCl, 50 mg/day                  Depression                     8 weeks                            BDI                                         Improvement in QoL
Duarte et al.58                Cognitive-behavioral               Major depression               3 months                    BDI, SF-36                            Improvement in depressive 
                                                     therapy                                                                                                                                                                                 symptoms
Lii et al.59                  Psychosocial intervention                 depression                    2-months                    BDI, SF-36                         Depression symptoms and QoL 
                                                                                                                                                                                                                                        improved significantly
Rocha et al.60                          No regular                    Depressive symptoms          No details                        HADS                                   A significant reduction of 
                                                psychological                                                                                                                                                               depression symptoms
                                                intervention
Jorm et al.61                 Relaxation techniques          Depressive symptoms          No details                       CCDAN                            Effective at reducing self-rated 
                                                                                                                                                                                                                                        depressive symptoms
Tsay et al.62                 Empowerment program                  Depression                     6 weeks                            BDI                        Improvement in depressive symptoms
Cho et al.63               Acupressure with massage               Depression                     4 weeks                            BDI                        Improvement in depressive symptoms
Kim et al.64                           Music therapy                           Depression                   No details                    No details                  Improvement in depressive symptoms
Babyak et al.65                  Aerobic exercise                  Major depressive              6 months                         HRSD                      Improvement in depressive symptoms
                                         (3 times per week)                        disorder
                                        & sertraline therapy                                
Kouidi et al.66                Intradialytic exercise              Emotional distress                 1 year                       BDI, HADS           Exercise training reduced emotional distress
Jung et al.67                 Aerobic and resistance                            -                    8 weeks - 12 months               SF-36                   Aerobic and resistance exercise improved 
                                                   exercise                                                                                                                                                        depression, and health-related QoL
BDI, Beck depression inventory; MMSE, mini mental state exam; MH (SF36), mental health (short form health survey 36); HADS, hospital anxiety and depression scale; RAND 36, RAND 36-item health survey; CCDAN,
the cochrane collaboration depression, anxiety and neurosis review group; HRSD, Hamilton rating scale for depression; QoL, quality of life.
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sion, more research is needed on their effec-
tiveness in dialysis and other chronic disease
patients. Alternative therapeutic approaches
Alternative therapeutic approaches have
always been attractive to chronically ill mental
patients since they satisfy their urge for trying
and using new ways for relieving their mental
and emotional symptoms and at the same time
they allow patients to detach themselves from
their current medication and possible invasive
methods of therapy. For instance, the effective-
ness of acupressure with massage in amelio-
rating fatigue and depression in HD patients
was examined by Cho and Tsay (2004).
Interestingly, the acupressure group reported
significantly greater improvements on both
fatigue and depression symptoms than the
respective group of patients who received the
regular unit care.63 Melody and rhythm are two
special ways to express feelings and emotions
and could be considered as an alternative way
of depression treatment. Kim and colleagues
(2006) showed that patients treated with
music therapy reported a lower score in
depression levels compared to the control
group who received no therapy.64 The positive
impact of music on emotional distress indices
was confirmed in a very recent study by Lin et
al., where the authors observed that the
patients who listened to music during the dial-
ysis sessions exhibited significant reductions
in perceived stressors and adverse reactions, a
fact that led the authors to conclude that music
could be beneficial for promoting wellbeing in
HD patients.77Exercise training
Low levels of physical activity have been
associated with depression.78 Aerobic and
resistance exercise have beneficial effects on
dialysis patients’ well-being. Specifically aero-
bic exercises improve not only physical func-
tioning but also improved nutritional status,
hematological indices, inflammatory
cytokines, depression, and health-related
QoL.15 For example, depressive HD patients
who participated in a moderate aerobic exer-
cise program improved their depressive symp-
toms and had lower relapse rates compared
with patients that received sertraline.65,79
Kouidi et al., (2010) examining the effect of
exercise training on Heart Rate Variability and
depression in HD patients, reported a benefi-
cial effect of an intra-dialytic exercise program
on both mental and cardiac autonomic distur-
bances.66 Also the same researchers showed a
relationship between depression and cardiac
autonomic dysfunction.66 Moreover, in HD
patients with significant motor symptoms
(restless legs syndrome) and sleep problems
(sleep apneas and periodic leg movements),
which also affect mental health, exercise has
been shown to improve symptomatology,
reduce depressive symptoms, and improve
QoL.80,81
Based on such and other beneficial results
of exercise, many research groups suggest that
exercise should be a mandatory not an option-
al intervention in HD patients because of its
beneficial effects on the overall health of this
population.15,67
Conclusions
Hemodialysis patients suffer from many
physical and mental conditions. Depression is
the most common psychological disorder
encountered in 20-30% of HD patients. While
hemodialysis is indisputably a life-sustaining
treatment for end-stage renal patients it also
has an adverse impact on the mental status of
these patients. 
Depression in HD patients results in poor
QoL and higher mortality risk and therefore
the need for its successful treatment should
receive special attention from nephrologists
and other specialists involved in renal
patients’ care. Many medications have been
shown to be effective for the treatment of
depression but due to patient’s poor adherence
in treatment as well as due to the high need for
medication related to the other comorbidities,
depression often remains untreated. To cope
with depressive symptoms and improve overall
QoL, it becomes imperative to implement a
multidimensional approach that includes dif-
ferent intervention strategies. 
Treatment of depression should be adminis-
tered by a team of professionals (psycholo-
gists, nurses, physicians, social workers and
others) applying different regimes and strate-
gies to provide a better care for the hemodialy-
sis population. It should be noted that the dial-
ysis environment could be an ideal place to
observe mood changes, behavior and mental
status, however, dialysis units do not usually
provide the appropriate privacy for discreet
discussions between the patients and health
care providers.  
In conclusion, depression is a disease that
needs to be treated the earliest possible in the
life of a hemodialysis patient since it can affect
his or her QoL and overall survival. More
research is needed to further explore the effec-
tiveness and safety of trusted or new methods
for the treatment of depression and depressive
symptoms in HD patients.
References
1. Miskulin DC, Athienites NV, Yan G, et al.
Comorbidity assessment using the index
of Coexistent Diseases in a multicenter
clinical trial. Kidney Int 2001;60:1498-510.
2. Finkelstein FO, Wuerth D, Finkelstein SH.
Health related quality of life and the CKD
patient: challenges for the nephrology
community. Kidney Int 2009;76:946-52.
3. Hedayati SS, Finkelstein FO.
Epidemiology, diagnosis, and management
of depression in patients with CKD. Am J
Kidney Dis 2009;54:741-52.
4. System URD. USRDS 2004 annual data
report: atlas of end-stage renal disease in
the United States. Bethesda: National
Institutes of Health, National Institute of
Diabetes and Digestive and Kidney
Diseases; 2004.
5. U.S. Department Of Health And Human
Services. Physical activity and Health: a
report of the surgeon general. 1999.
Available from: http://www.cdc.gov/nccd-
php/sgr/index.htm
6. Rosenthal Asher D, Ver Halen N, Cukor D.
Depression and nonadherence predict
mortality in hemodialysis treated end-
stage renal disease patients. Hemodial Int
2012;16:387-93.
7. WHO. Mental health: depression. 2012.
Available from: http://www.who.int/men-
tal_health/management/depression/en/ind
ex.html.
8. American Psychiatric Association.
Diagnostic criteria from DSM-IV-TR.
Washington, DC: American Psychiatric
Association; 2000. p 370.
9. American Psychiatric Association.
Diagnostic and statistical manual of men-
tal disorders. 4th ed.,Washington, DC:
American Psychiatric Association; 1994.
10. Kessler RC, Berglund P, Demler O, et al.
The epidemiology of major depressive dis-
order: results from the national comorbid-
ity survey replication (NCS-R). JAMA
2003;289:3095-105.
11. Breslau K. Ready for his close-up.
Newsweek 2004;144:12.
12. Moussavi S, Chatterji S, Verdes E, et al.
Depression, chronic diseases, and decre-
ments in health: results from the World
Health Surveys. Lancet 2007;370:851-8.
13. Bromet E, Andrade LH, Hwang I, et al.
Cross-national epidemiology of DSM-IV
major depressive episode. BMC Med 2011;
9:90.
14. Kimmel PL. Psychosocial factors in dialy-
sis patients. Kidney Int 2001;59:1599-613.
15. Mitrou GI, Grigoriou SS, Konstantopoulou
E, et al. Exercise training and depression
in ESRD: a review. Semin Dial
2013;26:604-13
16. Drayer RA, Piraino B, Reynolds CF 3rd, et
al. Characteristics of depression in
hemodialysis patients: symptoms, quality
of life and mortality risk. Gen Hosp
Psychiatry 2006;28:306-12.
                             Review
No
n c
om
me
rci
al 
us
e o
nly
                                 [Health Psychology Research 2015; 3:1811]                                                     [page 5]
17. Drayer RA, Mulsant BH, Lenze EJ, et al.
Somatic symptoms of depression in elderly
patients with medical comorbidities. Int J
Geriatr Psychiatry 2005;20:973-82.
18. Finkelstein FO, Finkelstein SH.
Depression in chronic dialysis patients:
assessment and treatment. Nephrol Dial
Transplant 2000;15:1911-3.
19. Garcia-Lizana F, Munoz-Mayorga I.
Telemedicine for depression: a systematic
review. Perspect Psychiatr Care
2010;46:119-26.
20. Theofilou P, Panagiotaki E. Factors affect-
ing quality of life in patients with end-
stage renal disease. Nursing 2010;49:174-
81.
21. Johnson S, Dwyer A. Patient perceived bar-
riers to treatment of depression and anxi-
ety in hemodialysis patients. Clin Nephrol
2008;69:201-6.
22. Kimmel PL. Depression in patients with
chronic renal disease. What we know and
what we need to know. J Psychosom Res
2002;53:951-6.
23. Chilcot, J., Wellsted D, Da Silva-Gane M,
Farrington K. Depression on dialysis.
Nephron Clin Pract 2008;108:256-64.
24. Chilcot J, Wellsted D, Farrington K.
Screening for depression while patients
dialyse: an evaluation. Nephrol Dial
Transplant 2008;23:2653-9.
25. Theofilou P. Medication adherence in
Greek hemodialysis patients: the contribu-
tion of depression and health cognitions.
Int J Behav Med 2013;20:311-8.
26. Rai M, Rustagi T, Rustagi S, Kohli R.
Depression, insomnia and sleep apnea in
patients on maintenance hemodialysis.
Indian J Nephrol 2011;21:223-9.
27. Araujo SM, de Bruin VM, Daher Ede F, et
al. Risk factors for depressive symptoms in
a large population on chronic hemodialy-
sis. Int Urol Nephrol 2012;44:1229-35.
28. Cohen SD, Norris L, Acquaviva K, et al.
Screening, diagnosis, and treatment of
depression in patients with end-stage
renal disease. Clin J Am Soc Nephrol
2007;2:1332-42.
29. Theofilou PA. Sexual functioning in chron-
ic kidney disease: the association with
depression and anxiety. Hemodial Int
2012;16:76-81.
30. Araujo SM, Mourão TC, Oliveira JL, et al.
Antimicrobial resistance of uropathogens
in women with acute uncomplicated cysti-
tis from primary care settings. Int Urol
Nephrol 2011;43:461-6.
31. Feroze U, Martin D, Reina-Patton A, et al.
Mental health, depression, and anxiety in
patients on maintenance dialysis. Iran J
Kidney Dis 2010;4:173-80.
32. Hedayati SS, Finkelstein FO.
Epidemiology, diagnosis, and management
of depression in patients with CKD. Am J
Kidney Dis 2009;54:741-52.
33. Kimmel PL, Peterson RA. Depression in
patients with end-stage renal disease
treated with dialysis: Has the time to treat
arrived? Clin J Am Soc Nephrol
2006;1:349-52.
34. Cukor D, Coplan J, Brown C, et al.
Depression and anxiety in urban
hemodialysis patients. Clin J Am Soc
Nephrol 2007;2:484-90.
35. Cukor D, Peterson RA, Cohen SD, Kimmel
PL. Depression in end-stage renal disease
hemodialysis patients. Nat Clin Pract
Nephrol 2006;2:678-87.
36. Kimmel PL, Peterson RA. Depression in
end-stage renal disease patients treated
with hemodialysis: tools, correlates, out-
comes, and needs. Semin Dial 2005;18:91-
7.
37. Kimmel PL, Thamer M, Richard CM, Ray
NF. Psychiatric illness in patients with
end-stage renal disease. Am J Med 1998;
105:214-21.
38. Kimmel PL, Weihs K, Peterson RA.
Survival in hemodialysis patients: the role
of depression. J Am Soc Nephrol 1993;4:12-
27.
39. Beck AT, Ward CH, Mendelson M, et al. An
inventory for measuring depression. Arch
Gen Psychiatry 1961;4:561-71.
40. Hathaway SR, McKinley JC. Manual for the
Minnesota Multiphasic personality inven-
tory. New York: Psychological Corporation;
1943.
41. Hathaway CR, McKinley JC. MMPI test
manual. Revised. New York: The
Psychological Corporation; 1961. p 22. 
42. Kadri ZN, Tye Cy. Role of Minnesota
Multiphasic Personality Inventory in the
diagnosis of psychiatric conditions.
Singapore Med J 1972;13:7-13.
43. Ware JE Jr, Sherbourne CD. The MOS 36-
item short-form health survey (SF-36). I.
Conceptual framework and item selection.
Med Care 1992;30:473-83.
44. Spitzer RL, Kroenke K, Williams JB.
Validation and utility of a self-report ver-
sion of PRIME-MD: the PHQ primary care
study. Primary Care Evaluation of Mental
Disorders. Patient Health Questionnaire.
JAMA 1999;282:1737-44.
45. Hamilton M. A rating scale for depression.
J Neurol Neurosurg Psychiatry 1960;23:56-
62.
46. Berrios GE, Bulbena-Villarasa A. The
Hamilton Depression Scale and the
numerical description of the symptoms of
depression. Psychopharmacol Ser
1990;9:80-92.
47. Radloff L. The CES-D Scale: a self-report
depression scale for research in the gener-
al population. Appl Psychol Measur
1977;1:385-401.
48. Zung W. A self-rating depression scale.
Arch Gen Psychiatry 1965;12:63-70.
49. Sonikian M, Metaxaki P, Papavasileiou D,
et al. Effects of interleukin-6 on depres-
sion risk in dialysis patients. Am J Nephrol
2010;31:303-8.
50. Giannaki CD, Sakkas GK, Karatzaferi C, et
al. Evidence of increased muscle atrophy
and impaired quality of life parameters in
patients with uremic restless legs syn-
drome. PLoS One 2011;6:e25180.
51. Lopes AA, Albert JM, Young EW, et al.
Screening for depression in hemodialysis
patients: associations with diagnosis,
treatment, and outcomes in the DOPPS.
Kidney Int 2004;66:2047-53.
52. Wuerth D, Finkelstein SH, Ciarcia J, et al.
Identification and treatment of depression
in a cohort of patients maintained on
chronic peritoneal dialysis. Am J Kidney
Dis 2001;37:1011-7.
53. Kennedy SH, Craven JL, Roin GM. Major
depression in renal dialysis patients - an
open trial of antidepressant therapy. J Clin
Psychiatry 1989;50:60-3.
54. Lee SK, Lee HS, Lee TB, et al. The effects
of antidepressant treatment on serum
cytokines and nutritional status in
hemodialysis patients. J Korean Med Sci
2004;19:384-9.
55. Koo JR, Yoon JY, Joo MH, et al. Treatment
of depression and effect of antidepression
treatment on nutritional status in chronic
hemodialysis patients. Am J Med Sci
2005;329:1-5.
56. Turk S, Atalay H, Altintepe L, et al.
Treatment with antidepressive drugs
improved quality of life in chronic
hemodialysis patients. Clin Nephrol 2006;
65:113-8.
57. Levy NB, Blumenfield M, Beasley CM Jr, et
al. Fluoxetine in depressed patients with
renal failure and in depressed patients
with normal kidney function. Gen Hosp
Psychiatry 1996;18:8-13.
58. Duarte PS, Miyazaki MC, Blay SL, Sesso R.
Cognitive-behavioral group therapy is an
effective treatment for major depression
in hemodialysis patients. Kidney Int
2009;76:414-21.
59. Lii YC, Tsay SL, Wang TJ. Group interven-
tion to improve quality of life in
haemodialysis patients. J Clin Nurs 2007;
16:268-75.
60. Rocha Augusto C, Krzesinski JM, Warling
X, et al. [The role of psychological inter-
ventions in dialysis: an exploratory study].
Nephrol Ther 2011;7:211-8. [Article in
French].
61. Jorm AF, Morgan AJ, Hetrick SE.
Relaxation for depression. Cochrane
Database Syst Rev 2008:CD007142.
62. Tsay SL, Hung LO. Empowerment of
patients with end-stage renal disease—a
randomized controlled trial. Int J Nurs
                                                                                                                             Review
No
n c
om
me
rci
al 
us
e o
nly
[page 6]                                                       [Health Psychology Research 2015; 3:1811]
Stud 2004;41:59-65.
63. Cho YC, Tsay SL. The effect of acupressure
with massage on fatigue and depression
in patients with end-stage renal disease. J
Nurs Res 2004;12:51-9.
64. Kim KB, Lee MH, Sok SR. [The effect of
music therapy on anxiety and depression
in patients undergoing hemodialysis].
Taehan Kanho Hakhoe Chi 2006;36:321-9.
[Article in Korean]
65. Babyak M, Blumenthal JA, Herman S, et al.
Exercise treatment for major depression:
maintenance of therapeutic benefit at 10
months. Psychosom Med 2000;62:633-8.
66. Kouidi E, Karagiannis V, Grekas D, et al.,
Depression, heart rate variability, and
exercise training in dialysis patients. Eur
J Cardiovasc Prev Rehabil 2010;17:160-7.
67. Jung TD,  Park SH. Intradialytic exercise
programs for hemodialysis patients.
Chonnam Med J 2011;7:61-5.
68. Patel SS, Shah VS, Peterson RA, Kimmel
PL. Psychosocial variables, quality of life,
and religious beliefs in ESRD patients
treated with hemodialysis. Am J Kidney
Dis 2002;40:1013-22.
69. Cohen LM, Tessier EG, Germain MJ, Levy
NB. Update on psychotropic medication
use in renal disease. Psychosomatics
2004;45:34-48.
70. Kalender B, Ozdemir AC, Yalug I,
Dervisoglu E. Antidepressant treatment
increases quality of life in patients with
chronic renal failure. Ren Fail 2007;29:
817-22.
71. Kimura H, Ozaki N. Diagnosis and treat-
ment of depression in dialysis patients.
Ther Apher Dial 2006;10:328-32.
72. Beck AT. Depression: clinical, experimen-
tal, and theoretical aspects. New York:
Hoeber Medical Division; 1967. p 370.
73. Beck AT, Rush AJ, Shaw BF, Emery G.
Cognitive therapy of depression. New
York: The Guilford Press; 1979.
74. Leake R, Friend R, Wadhwa N. Improving
adjustment to chronic illness through
strategic self-presentation: an experimen-
tal study on a renal dialysis unit. Health
Psychol 1999;1:54-62.
75. Symister P, Friend R. The influence of
social support and problematic support on
optimism and depression in chronic ill-
ness: a prospective study evaluating self-
esteem as a mediator. Health Psychol
2003;22:123-9.
76. Krespi MR, Oakley D, Bone M, et al. [The
effects of visual imagery on adjustment
and quality in life of hemodialysis
patients]. Turk Psikiyatri Derg
2009;20:255-68. [Article in Turkish]
77. Lin YJ, Lu KC, Chen CM, Chang CC. The
effects of music as therapy on the overall
well-being of elderly patients on mainte-
nance hemodialysis. Biol Res Nurs
2012;14:277-85.
78. Anand S, Johansen KL, Grimes B, et al.
Physical activity and self-reported symp-
toms of insomnia, restless legs syndrome,
and depression: the comprehensive dialy-
sis study. Hemodial Int 2013;17:50-8.
79. Dunn AL, Trivedi MH, O’Neal HA. Physical
activity dose-response effects on outcomes
of depression and anxiety. Med Sci Sports
Exerc 2001;33:S587-97.
80. Giannaki CD, Sakkas GK, Karatzaferi C, et
al. Effect of exercise training and
dopamine agonists in patients with ure-
mic restless legs syndrome: a six-month
randomized, partially double-blind, place-
bo-controlled comparative study. BMC
Nephrol 2013;14:194.
81. Giannaki CD, Hadjigeorgiou GM,
Karatzaferi C, et al. A single-blind random-
ized controlled trial to evaluate the effect
of 6 months of progressive aerobic exer-
cise training in patients with uraemic
restless legs syndrome. Nephrol Dial
Transplant 2013;28:2834-40.
                             Review
No
n c
om
me
rci
al 
us
e o
ly
